3b Blackbio Dx Ltd vs Aspira Pathlab Diagnostics Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 24, 2026

Key Highlights

The Latest Trading Price of 3B Blackbio DX Ltd is ₹ 1332 as of 23 Oct 15:30 . The P/E Ratio of 3B Blackbio DX Ltd changed from 1.9 on March 2021 to 29 on March 2025 . This represents a CAGR of 72.48% over 5 yearsThe P/E Ratio of Aspira Pathlab & Diagnostics Ltd changed from 43.3 on March 2025 to 43.3 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of 3B Blackbio DX Ltd changed from ₹ 213.76 crore on March 2021 to ₹ 1387 crore on March 2025 . This represents a CAGR of 45.37% over 5 yearsThe Market Cap of Aspira Pathlab & Diagnostics Ltd changed from ₹ 31.91 crore on March 2024 to ₹ 87.73 crore on March 2025 . This represents a CAGR of 65.81% over 2 years The revenue of 3B Blackbio DX Ltd for the Jun '26 is ₹ 39.63 crore as compare to the Mar '26 revenue of ₹ 45.58 crore. This represent the decline of -13.05% The revenue of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of 3B Blackbio DX Ltd for the Jun '26 is ₹ 14.67 crore as compare to the Mar '26 ebitda of ₹ 18.64 crore. This represent the decline of -21.3% The ebitda of Aspira Pathlab & Diagnostics Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of 3B Blackbio DX Ltd changed from ₹ 11.3 crore to ₹ 8.98 crore over 9 quarters. This represents a CAGR of -9.71% The net profit of Aspira Pathlab & Diagnostics Ltd changed from ₹ 0.05 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The Dividend Payout of 3B Blackbio DX Ltd changed from 391.92 % on March 2021 to 8.69 % on March 2026 . This represents a CAGR of -47.00% over 6 yearsThe Dividend Payout of Aspira Pathlab & Diagnostics Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About 3B Blackbio DX Ltd

3D Blackbio DX Limited, formerly known as Kilpest India Limited was incorporated on May 25, 1972 as one of India's leading agro-business companies.
Thereafter, the holding Company, Kilpest India Limited got merged with 3B BlackBio Biotech India Limited and as per the Scheme of Amalgamation, the name of the Company was changed from Kilpest India Limited to 3B BlackBio DX Limited in August, 2023. The Company is a leading Indian biotech firm focused on molecular diagnostics (PCR kits, enzymes, reagents for diseases like cancer/ infectious diseases) under the 'TRUPCR' brand, alongside developing Next-Gen Sequencing (NGS) assays (TRUNGS) & Rapid Tests (TRURAPID), while continuing its traditional agrochemicals business (pesticides, bio-products), serving both labs and government sectors, driven by R&D for innovative solutions.

About Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab & Diagnostics Limited (ASDL) was incorporated in July, 1973.
ASDL is a leading pathology specialist, with Pan-India presence.
It offer pathology and diagnostic services to individual patients, hospitals, other healthcare providers, and businesses.
The Company, with a wider presence in Maharashtra India, enjoys a loyal customer base, that reflects on its strength as a brand, providing superior diagnostic testing and services. Presently, Company is engaged into the business of running, owning, managing and administering Diagnostics Centers.
Its principal activities consist of pathology investigation services, radiology investigation services and other related healthcare services at Diagnostic Centres in Mumbai. ASDL ideology is founded on technological supremacy, patient centric approach, and dependable diagnostic results.

FAQs for the comparison of 3B Blackbio DX Ltd and Aspira Pathlab & Diagnostics Ltd

Which company has a larger market capitalization, 3B Blackbio DX Ltd or Aspira Pathlab & Diagnostics Ltd?

Market cap of 3B Blackbio DX Ltd is 1,144 Cr while Market cap of Aspira Pathlab & Diagnostics Ltd is 129 Cr

What are the key factors driving the stock performance of 3B Blackbio DX Ltd and Aspira Pathlab & Diagnostics Ltd?

The stock performance of 3B Blackbio DX Ltd and Aspira Pathlab & Diagnostics Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for 3B Blackbio DX Ltd and Aspira Pathlab & Diagnostics Ltd?

As of October 24, 2026, the 3B Blackbio DX Ltd stock price is INR ₹1332.95. On the other hand, Aspira Pathlab & Diagnostics Ltd stock price is INR ₹126.05.

How do dividend payouts of 3B Blackbio DX Ltd and Aspira Pathlab & Diagnostics Ltd compare?

To compare the dividend payouts of 3B Blackbio DX Ltd and Aspira Pathlab & Diagnostics Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.